Why it matters
CBD is the second most abundant cannabinoid in most modern cannabis cultivars and the dominant cannabinoid in hemp. Unlike THC, it does not directly activate CB1 — at low doses it appears to act as a negative allosteric modulator at CB1 (blunting THC’s effects) and as an agonist at 5-HT1A serotonin receptors, among other actions. FDA approval (as Epidiolex) exists for treatment-resistant paediatric epilepsy.
In practice
Available formats include tinctures, gummies, capsules, topicals, vapes, and flower. Dose-response is non-linear and individual; the appropriate starting dose for general use is typically far lower than the doses studied in epilepsy trials. Bioavailability differs substantially by route.
Common confusion
“CBD doesn’t do anything” and “CBD cures everything” are both wrong. CBD has real pharmacological effects, narrower than marketing implies and broader than dismissal allows.
This glossary entry is editorial content reviewed against primary sources. It is not medical advice. See our Editorial Policy.
References
- FDA – Regulation of Cannabis and Cannabis-Derived Products, Including CBD
- FDA – What the FDA Is Doing to Protect Consumers from CBD in Foods
- Benefits, Safety and Regulation of CBD in Consumer Products (NCBI/PMC)
External sources for educational reference. Alternative Pharm Press is not affiliated with these organizations.